Exact Sciences
EXAS
#1154
Rank
โ‚น1.722 T
Marketcap
โ‚น9,079
Share price
-0.07%
Change (1 day)
71.23%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

Revenue for Exact Sciences (EXAS)

Revenue in 2025 (TTM): โ‚น266.71 Billion

According to Exact Sciences's latest financial reports the company's current revenue (TTM ) is โ‚น276.87 Billion. In 2024 the company made a revenue of โ‚น236.67 Billion an increase over the revenue in the year 2023 that were of โ‚น208.10 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exact Sciences from 2001 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น266.71 B12.69%
2024 โ‚น236.67 B13.73%
2023 โ‚น208.10 B20.66%
2022 โ‚น172.47 B31.13%
2021 โ‚น131.52 B20.59%
2020 โ‚น109.07 B74.54%
2019 โ‚น62.48 B96.65%
2018 โ‚น31.77 B87.1%
2017 โ‚น16.98 B151.49%
2016 โ‚น6.75 B157.67%
2015 โ‚น2.62 B2199.87%
2014 โ‚น0.11 B-55.49%
2013 โ‚น0.25 B12.83%
2012 โ‚น0.22 B3.03%
2011 โ‚น0.22 B-8.04%
2010 โ‚น0.23 B8.47%
2009 โ‚น0.22 B
2007 โ‚น0.11 B-45.25%
2006 โ‚น0.21 B10%
2005 โ‚น0.19 B-10.52%
2004 โ‚น0.21 B61.81%
2003 โ‚น0.13 B207.06%
2002 โ‚น43.01 M1652.4%
2001 โ‚น2.45 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Myriad Genetics
MYGN
โ‚น74.14 B-73.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Antares Pharma
ATRS
โ‚น16.52 B-94.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Veracyte
VCYT
โ‚น44.48 B-83.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Biocept
BIOC
-โ‚น0.31 Billion-100.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น4.269 T 1,442.00%๐Ÿ‡ซ๐Ÿ‡ท France